Fludarabine
T-cell Childhood Acute Lymphoblastic Leukemia
Case Comprehensive Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the T-cell Childhood Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
METHOTREXATE National Cancer Institute (NCI) | Phase 3 | BBB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 3 | BB |
Calcium folinate pentahydrate National Cancer Institute (NCI) | Phase 3 | BB |
ASPARAGINASE National Cancer Institute (NCI) | Phase 3 | BB |
ETOPOSIDE National Cancer Institute (NCI) | Phase 3 | BB |
View all 28 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →